產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
400-999-210024小時(shí)服務(wù)熱線
Hep 3B2.1-7 (人肝癌細(xì)胞) (STR鑒定正確)
貨號(hào)：CL-0102
規(guī)格：1×10?cells/T25培養(yǎng)瓶
價(jià)格： ￥1600
生長培養(yǎng)基：MEM（含NEAA）＋10% FBS＋1% P/S
產(chǎn)品概述
| 名稱 | Hep 3B2.1-7 (人肝癌細(xì)胞) (STR鑒定正確) |
| 別稱 | Hep 3B2_1-7; Hep 3B2; HEP-3B2; HEP3B2; Hep-3B; HEP-3B; Hep 3B; Hep3B; HEP3B |
| 種屬 | 人 |
| 生長特性 | 貼壁細(xì)胞 |
| 細(xì)胞形態(tài) | 上皮細(xì)胞樣 |
| 凍存條件 | 凍存液：55% 基礎(chǔ)培養(yǎng)基+40%FBS+5%DMSO 溫度：液氮 |
| 培養(yǎng)方案A（默認(rèn)） |
生長培養(yǎng)基:
培養(yǎng)條件:
氣相：空氣，95%；CO2，5%, 溫度：37℃
|
| 推薦傳代比例 | 1:2-1:3 |
| 推薦換液頻率 | 2-3次/周 |
| 背景描述 | Hep 3B2.1-7細(xì)胞是來自8歲男性黑人的組織。Hep 3B2.1-7細(xì)胞的染色體模式數(shù)目為60，在裸鼠中能致瘤。Hep 3B2.1-7細(xì)胞整合了完整的乙型肝炎病毒基因組，需在2級(jí)生物安全防護(hù)下操作。 |
| 年齡（性別） | 男性；8歲 |
| 組織來源 | 肝細(xì)胞癌，肝 |
| 細(xì)胞類型 | 腫瘤細(xì)胞 |
| 腫瘤類型 | 肝膽癌細(xì)胞 |
| 生物安全等級(jí) | BSL-2 |
| 倍增時(shí)間 | ~40-50 hours |
| 致瘤性 | Yes, in nude mice. |
| 基因表達(dá)情況 | alpha fetoprotein (alpha-fetoprotein); hepatitis B surface antigen (HBsAg); albumin; alpha2 macroglobulin (alpha-2-macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin;, alpha1 antichymotrypsin (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; plasminogen; complement (C3, C4); C3 activator; fibrinogen; alpha1 acid glycoprotein (alpha-1 acid glycoprotein);, alpha2 HS glycoprotein (alpha-2-HS-glycoprotein); beta lipoprotein (beta-lipoprotein); retinol binding protein (retinol- |
| 保藏機(jī)構(gòu) | ATCC; HB-8064 BCRC; 60434 BCRJ; 0357 DSMZ; ACC-93 ECACC; 86062703 |
STR鑒定
-
STR位點(diǎn)信息
Amelogenin X CSF1PO 8 D2S1338 21,25 D3S1358 15 D5S818 13 D7S820 8,10 D8S1179 12 D13S317 12,14 D16S539 10 D18S51 20 D19S433 12.2,14 D21S11 30,31 FGA 18 PentaD 12,14 PentaE 5,16 TH01 6,7 TPOX 9 vWA 17 D6S1043 12,17 D12S391 17 D2S441 10,12 -
STR鑒定圖
-
參考文獻(xiàn)
-
SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma(2022/11/15)
作者：Hu, Qingqing, Liu, Qiuhong, Zhao, Yalei, Zhang, Lingjian, Li, Lanjuan
期刊：Biomarker Research
DOI：10.1186/s40364-022-00422-z
影響因子 ：11.100
-
The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP(2023/10/12)
作者：Zelin Tian, Chen Xu, Weixiang He
期刊：CANCER LETTERS
DOI：10.1016/j.canlet.2023.216439
影響因子 ：9.700
引用產(chǎn)品：CL-0102
-
LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway(2021/11/27)
作者：Ying Xing,Yang Liu，Zhong Qi
期刊：Cellular & Molecular Biology Letters
DOI：10.1186/s11658-021-00295-4
影響因子 ：8.300
-
5′-tiRNA-Gln inhibits hepatocellular carcinoma progression by repressing translation through the interaction with eukaryotic initiation factor 4A-I(2023/03/28)
作者：Chengdong Wu, Dekai Liu, Lufei Zhang
期刊：Frontiers of Medicine
影響因子 ：8.100
-
Stabilization of SETD3 by deubiquitinase USP27 enhances cell proliferation and hepatocellular carcinoma progression(2022/01/12)
作者：Tingting Zou, Yang Wang, Ling Dong
期刊：CELLULAR AND MOLECULAR LIFE SCIENCES
DOI：10.1007/s00018-021-04118-9
影響因子 ：8.000
引用產(chǎn)品：CL-0102
-
RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4(2023/12/01)
作者：Chun Wang, Zhihang Chen, Yun Yi
期刊：ONCOGENE
DOI：10.1038/s41388-023-02902-4
影響因子 ：8.000
引用產(chǎn)品：CL-0102
-
Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination(2023/11/25)
作者：Kun Cao, Ruonan Wang, Lianhai Li
期刊：ONCOGENE
DOI：10.1038/s41388-023-02898-x
影響因子 ：8.000
引用產(chǎn)品：CL-0102
-
USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis(2018/03/02)
作者：Ling Dong, Le Yu, Chunrong Bai
期刊：Oncogene
影響因子 ：8.000
引用產(chǎn)品：CL-0102
-
How CLSPN could demystify its prognostic value and potential molecular mechanism for hepatocellular carcinoma: A crosstalk study(2024/03/11)
作者：Yanlong Shi, Yizhu Wang, Kaiyi Niu
期刊：COMPUTERS IN BIOLOGY AND MEDICINE
DOI：10.1016/j.compbiomed.2024.108260
影響因子 ：7.700
引用產(chǎn)品：CL-0102
-
RBBP7, regulated by SP1, enhances the Warburg effect to facilitate the proliferation of hepatocellular carcinoma cells via PI3K/AKT signaling(2024/02/18)
作者：Yuan Fang, WeiQiang Tang, Siming Qu
期刊：Journal of Translational Medicine
DOI：10.1186/s12967-024-04964-8
影響因子 ：7.400
引用產(chǎn)品：CL-0102
-
JMJD6–BRD4 complex stimulates lncRNA HOTAIR transcription by binding to the promoter region of HOTAIR and induces radioresistance in liver cancer stem cells(2023/10/25)
作者：Ruifeng Pei, Le Zhao, Yiren Ding
期刊：Journal of Translational Medicine
DOI：10.1186/s12967-023-04394-y
影響因子 ：7.400
引用產(chǎn)品：CL-0102
-
Dual role of PID1 in regulating apoptosis induced by distinct anticancer-agents through AKT/Raf-1-dependent pathway in hepatocellular carcinoma(2023/04/28)
作者：Jian Yang, Senlin Li, Jialuo He
期刊：Cell Death Discovery
DOI：10.1038/s41420-023-01405-1
影響因子 ：7.000
-
Transfer RNA‐derived fragment 5′tRF‐Gly promotes the development of hepatocellular carcinoma by direct targeting of carcinoembryonic antigen‐related cell adhesion molecule 1(2022/08/16)
作者：Dekai Liu, Chengdong Wu, Jingjie Wang
期刊：CANCER SCIENCE
影響因子 ：6.518
引用產(chǎn)品：CL-0102
-
Hepatic stellate cell‐released CXCL1 aggravates HCC malignant behaviors through the MIR4435‐2HG/miR‐506‐3p/TGFB1 axis(2022/12/04)
作者：Shaling Li, Xingwang Hu, Songman Yu
期刊：CANCER SCIENCE
影響因子 ：6.518
引用產(chǎn)品：CL-0102
-
VEZF1, destabilized by STUB1, affects cellular growth and metastasis of hepatocellular carcinoma by transcriptionally regulating PAQR4(2022/10/14)
作者：Xiaobao Shi, Pengfei Zhao, Gang Zhao
期刊：Cancer Gene Therapy
DOI：10.1038/s41417-022-00540-8
影響因子 ：6.400
-
An NAD+ -Dependent Deacetylase SIRT7 Promotes HCC Development Through Deacetylation of USP39(2020/07/09)
作者：Ling Dong, Le Yu, Hui Li
期刊：iScience
DOI：10.1016/j.isci.2020.101351
影響因子 ：5.800
引用產(chǎn)品：CL-0102
-
CREB3L4 promotes hepatocellular carcinoma progression and decreases sorafenib chemosensitivity by promoting RHEB-mTORC1 signaling pathway(2024/01/09)
作者：Zhengchen Jiang, Bowen Shi, Yun Zhang
期刊：iScience
DOI：10.1016/j.isci.2024.108843
影響因子 ：5.800
引用產(chǎn)品：CL-0102
-
Establishment of Prognostic Signatures of N6-Methyladenosine-Related lncRNAs and Their Potential Functions in Hepatocellular Carcinoma Patients(2022/06/06)
作者：Xianbin Wu,?Zhejun Deng,?Xiaomin Liao?
期刊：Frontiers in Oncology
影響因子 ：5.738
-
TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/YAP pathway(2024/03/12)
作者：Bo Shu, Yingxia Zhou, Guoqiong Lei
期刊：CANCER SCIENCE
影響因子 ：5.700
引用產(chǎn)品：CL-0102
-
BMP9-ID1 Pathway Attenuates N6-Methyladenosine Levels of CyclinD1 to Promote Cell Proliferation in Hepatocellular Carcinoma(2024/01/12)
作者：Han Chen, Mingming Zhang, Jianhao Li
期刊：INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
影響因子 ：5.600
引用產(chǎn)品：CL-0102
-
Lack of MOF Decreases Susceptibility to Hypoxia and Promotes Multidrug Resistance in Hepatocellular Carcinoma via HIF-1α(2021/09/01)
作者：Meng Wang, Haoyu Liu, Xu Zhang
期刊：Frontiers in Cell and Developmental Biology
影響因子 ：5.500
-
The anti-hepatocellular carcinoma effect of Aidi injection was related to the synergistic action of cantharidin, formononetin, and isofraxidin through BIRC5, FEN1, and EGFR(2023/09/25)
作者：Shan Lu, Jiaqi Huang, Jingyuan Zhang
期刊：JOURNAL OF ETHNOPHARMACOLOGY
影響因子 ：5.400
引用產(chǎn)品：CL-0102
-
The bioactive ingredients in Actinidia chinensis Planch. Inhibit liver cancer by inducing apoptosis(2021/08/21)
作者：Zongchao Hong, Yi Lu, Chongwang Ran
期刊：Journal Of Ethnopharmacology
影響因子 ：5.400
-
Detection of CSTF2 by nano fluorescent probe and its correlation with malignant biological characteristics in liver cancer(2023/11/15)
作者：Zhongmin Jiang, Xiaozhi Liu, Yongqing Deng
期刊：American Journal of Cancer Research
DOI：PMID:38058835
影響因子 ：5.300
引用產(chǎn)品：CL-0102
-
Upregulation of FAM134B inhibits endoplasmic reticulum stress-related degradation protein expression and promotes hepatocellular carcinogenesis(2023/09/20)
作者：Houhong Wang, Lu Liu, Huihui Gong
期刊：JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
影響因子 ：5.300
-
Asymmetric total synthesis and anti-hepatocellular carcinoma profile of enantiopure euphopilolide and jolkinolide E(2023/06/22)
作者：Xin Li, Jian Chen, Kaixuan Luo
期刊：BIOORGANIC CHEMISTRY
DOI：10.1016/j.bioorg.2023.106688
影響因子 ：5.100
-
Chaetocochin J exhibits anti-hepatocellular carcinoma effect independent of hypoxia(2023/06/25)
作者：Ping Hu, Linzhen Hu, Yizhan Chen
期刊：BIOORGANIC CHEMISTRY
DOI：10.1016/j.bioorg.2023.106701
影響因子 ：5.100
-
SLC39A10 Upregulation Predicts Poor Prognosis, Promotes Proliferation and Migration, and Correlates with Immune Infiltration in Hepatocellular Carcinoma(2022/11/14)
作者：Zuyi Ma, Zhenchong Li, Shujie Wang
期刊：Journal of Hepatocellular Carcinoma
影響因子 ：4.962
引用產(chǎn)品：CL-0102
-
Proteoglycan-4 predicts good prognosis in patients with hepatocellular carcinoma receiving transcatheter arterial chemoembolization and inhibits cancer cell migration in vitro.(2022/11/11)
作者：Yuan Guo, Hong Tao Hu, Shi Jun Xu, Wei Li Xia, Yan Zhao, Xiao Hui Zhao, Wen Bo Zhu, Fang Ting Li, Hai Liang Li
期刊：Frontiers in Oncology
影響因子 ：4.700
-
Circ_0007429/miR-637/TRIM71/Ago2 axis participates in the regulation of proliferation, migration, invasion, apoptosis, and aerobic glycolysis of HCC(2023/03/15)
作者：Lilan Fan, Panpan Xia, Jing Wang
期刊：MOLECULAR CARCINOGENESIS
DOI：10.1002/mc.23526
影響因子 ：4.600
-
Hepatoprotective effects of aspirin on diethylnitrosamine-induced hepatocellular carcinoma in rats by reducing inflammation levels and PD-L1 expression(2023/12/04)
作者：Yikai Wang, Muqi Wang, Chenrui Liu
期刊：Scientific Reports
DOI：10.1038/s41598-023-48812-z
影響因子 ：4.600
引用產(chǎn)品：CL-0102
-
Circ_0027791 contributes to the growth and immune evasion of hepatocellular carcinoma via the miR-496/programmed cell death ligand 1 axis in an m6A-dependent manner(2024/03/28)
作者：Furong Yu, Peifei Fang, Yonghong Fang
期刊：ENVIRONMENTAL TOXICOLOGY
影響因子 ：4.500
引用產(chǎn)品：CL-0102
-
Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways(2021/02/09)
作者：Liang Yu, Meng Wang, Yang Yang
期刊：Plos Computational Biology
DOI：10.1371/journal.pcbi.1008696
影響因子 ：4.300
-
ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway(2021/06/07)
作者：Jianwen Liu, Ruiqing Liu, Yuyan Liu
期刊：Cell Cycle
DOI：10.1080/15384101.2021.1919828
影響因子 ：4.300
-
LINC00886 Facilitates Hepatocellular Carcinoma Tumorigenesis by Sequestering microRNA-409-3p and microRNA-214-5p(2023/06/07)
作者：Lu Li, Rong Ai, Xiwei Yuan
期刊：Journal of Hepatocellular Carcinoma
影響因子 ：4.100
-
Circular RNA circBNC2 facilitates glycolysis and stemness of hepatocellular carcinoma through the miR-217/high mobility group AT-hook 2 (HMGA2) axis.(2023/06/09)
作者：Yan Feng, Shufeng Xia, Junlan Hui
期刊：Heliyon
DOI：10.1016/j.heliyon.2023.e17120
影響因子 ：4.000
-
Long noncoding RNA HULC regulates the NF-κB pathway and represents a promising prognostic biomarker in liver cancer(2022/10/10)
作者：Shihai Liu, Lakshmi Huttad, Guifang He
期刊：Cancer Medicine
影響因子 ：4.000
-
The abrogation of GRP78 sensitizes liver cancer cells to lysionotin by enhancing ER stress-mediated pro-apoptotic pathway(2023/06/16)
作者：Ying Zou, Hewen Shi, Haiyan Lin
期刊：CELL STRESS & CHAPERONES
DOI：10.1007/s12192-023-01358-5
影響因子 ：3.800
-
miR-10b-5p promotes tumor growth by regulating cell metabolism in liver cancer via targeting SLC38A2(2024/02/23)
作者：Mingzhi Xia, Jie Chen, Yingyun Hu
期刊：CANCER BIOLOGY & THERAPY
DOI：10.1080/15384047.2024.2315651
影響因子 ：3.600
引用產(chǎn)品：CL-0102
-
Atractylenolide II regulates the proliferation, ferroptosis, and immune escape of hepatocellular carcinoma cells by inactivating the TRAF6/NF-κB pathway(2024/05/06)
作者：Yujie Lin, Ke Chen, Min Zhu
期刊：NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
DOI：10.1007/s00210-024-03046-2
影響因子 ：3.600
引用產(chǎn)品：CL-0102
-
HuR-induced circ_0082319 contributes to hepatocellular carcinoma by elevating PTK2 through miR-505-3p(2023/10/25)
作者：Chuntang Qin, Shuyan Liu, Weibin Chen
期刊：NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
DOI：10.1007/s00210-023-02793-y
影響因子 ：3.600
引用產(chǎn)品：CL-0102
-
Active compounds and potential targets of Shuganning injection in the treatment of hepatocellular carcinoma by network pharmacology and in vitro validation(2023/03/04)
作者：Xiao Han, Jiayan Huang, Jia Lu
期刊：NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
DOI：10.1007/s00210-023-02432-6
影響因子 ：3.600
-
LncRNA FAM13A-AS1, transcriptionally regulated by PHOX2B, modulates hepatocellular carcinoma chemoresistance via stabilizing PPARγ(2023/06/16)
作者：Daowen Ye, Jun Ma, Tingdong Yu
期刊：GENE
DOI：10.1016/j.gene.2023.147570
影響因子 ：3.500
-
Exosomal IGFBP2 derived from highly metastatic promotes hepatocellular carcinoma metastasis by inducing epithelial mesenchymal transition(2024/03/14)
作者：Yongyuan Zheng, Weibing Li, Yansong Huang
期刊：GENE
DOI：10.1016/j.gene.2024.148374
影響因子 ：3.500
引用產(chǎn)品：CL-0102
-
FXR1 promotes proliferation, invasion and migration of hepatocellular carcinoma in?vitro and in?vivo(2022/11/22)
作者：Kun Zhao, Jie Gao, Jihua Shi, Chengcheng Shi
期刊：Oncology Letters
影響因子 ：3.111
引用產(chǎn)品：CL-0102
-
Transcriptome-Wide Dynamics of m7G-Related LncRNAs during the Progression from HBV Infection to Hepatocellular Carcinoma(2023/12/19)
作者：Min Shi, Shunshun Zhu, Linying Sun
期刊：Frontiers in Bioscience-Landmark
影響因子 ：3.100
引用產(chǎn)品：CL-0102
-
Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis(2021/1/12)
作者：Lili Zhao, Ning Ma, Gaihong Liu
期刊：Digestive Diseases And Sciences
DOI：10.1007/s10620-020-06787-1
影響因子 ：3.100
-
NFYAv1 is a Tumor-Promoting Transcript Associated with Poor Prognosis of Hepatocellular Carcinoma(2023/01/21)
作者：Zigang Li, Chengshan You, Jun Huang
期刊：MEDICAL SCIENCE MONITOR
影響因子 ：3.100
-
Matrine inhibits cell proliferation, invasion, and stem cell formation in hepatocellular carcinoma by regulating the ELAVL1/RBM3-mediated Wnt/β-catenin signaling pathway(2024/01/23)
作者：Chunhua Song, Hongwei Li, Zhengchun Huang
期刊：Chemical Biology & Drug Design
影響因子 ：3.000
引用產(chǎn)品：CL-0102
-
Silencing of keratin 15 impairs viability and mobility while facilitating the doxorubicin chemosensitivity by inactivating the β?catenin pathway in liver cancer(2023/08/30)
作者：Junying Wang, Guangyu Zhu
期刊：Oncology Letters
影響因子 ：2.900
引用產(chǎn)品：CL-0102 CL-0103 CL-0120 CL-0139 CL-0415 PB180120 PM150110 PM150210
-
Role of SLC39A6 in the development and progression of liver cancer(2022/01/11)
作者：Zhen Wan, Xuzhen Wang
期刊：Oncology Letters
影響因子 ：2.900
-
CKS1B promotes the progression of hepatocellular carcinoma by activating JAK/STAT3 signal pathway(2021/07/14)
作者：Xitao Liu, Defang Zhao
期刊：Animal Cells and Systems
DOI：10.1080/19768354.2021.1953142
影響因子 ：2.900
-
Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3(2023/06/16)
作者：Zongqiang Hu, Yingpeng Zhao, Laibang Li
期刊：MOLECULAR BIOLOGY REPORTS
DOI：10.1007/s11033-023-08492-4
影響因子 ：2.800
-
Propofol enhances the lethality of cisplatin on liver cancer cells by up-regulating miR-195-5p(2021/11/19)
作者：Lan Gao, Xiufeng Zhang
期刊：Tissue & Cell
DOI：10.1016/j.tice.2021.101680
影響因子 ：2.600
-
Overexpression of PLK1 Molecule Following Incomplete Thermal Ablation Promotes the Proliferation and Invasion of Residual Hepatocellular Carcinoma(2024/05/23)
作者：Tong Kang, Jiamin Chen, Weijun Wan
期刊：MOLECULAR BIOTECHNOLOGY
DOI：10.1007/s12033-024-01181-y
影響因子 ：2.600
引用產(chǎn)品：CL-0102
-
LINC00665 target let-7i/HMGA1 promotes the proliferation and invasion of hepatoma cells(2024/02/07)
作者：Bochao Zhang, Siyuan Ma, Ping Zhu
期刊：MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
DOI：10.1016/j.mrfmmm.2024.111852
影響因子 ：2.300
引用產(chǎn)品：CL-0102
-
Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma(2023/05/27)
作者：Hewen Shi, Ying Zou, Xiaoxue Wang
期刊：Discover Oncology
DOI：10.1007/s12672-023-00699-y
影響因子 ：2.200
引用產(chǎn)品：CL-0102
-
Polygonatum sibiricum Polysaccharide Inhibited Liver Cancer in a Simulated Tumor Microenvironment by Eliminating TLR4/STAT3 Pathway(2023/09/01)
作者：Yunke Xu, Yong Guo, Changyou Lu
期刊：BIOLOGICAL & PHARMACEUTICAL BULLETIN
影響因子 ：2.000
-
Inhibitory Effect of Hernandezine on the Proliferation of Hepatocellular Carcinoma(2023/02/01)
作者：Chiufai Kuok, Qi Wang, Pedro Fong
期刊：BIOLOGICAL & PHARMACEUTICAL BULLETIN
影響因子 ：2.000
FAQs
Q：{{item.question}}
A：
產(chǎn)品資料
識(shí)別碼示意圖
.png "梅文強(qiáng)")
